Phase 2 N=10 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
Churg Strauss Syndrome
Primary: Number of Participants With Indicated Side Effects — 3; 1; 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=118 Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
Churg-Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis
Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESI) — 69; 26; 42 Participants
Phase 3 N=100 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
Churg-Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 98; 38 Participants
N/A N=120 Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Churg-Strauss Syndrome · Eosinophilic Asthma · Eosinophilic Esophagitis
Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants
Phase 2 N=24 Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Chronic Rhinosinusitis (Diagnosis) · Nasal Polyps · Eosinophilia
Primary: Change in Nasal Polyp Score — .9; .3 score on a scale
Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Phase 3 N=295 Steroids In Eosinophil Negative Asthma
Asthma
Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…
Phase 4 N=13 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
ALLERGIC ASTHMA
Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants
N/A N=31 Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment
Smoking
Primary: Airway Blood Flow — 2.13; 13.05 ΔQaw (ul/min/ml)
Early Phase 1 N=48 GSNOR Phenotyping/GSNO Challenge in Severe Asthma
Asthma
Primary: FeNO — 14.3; 34.3; 36.0; 49 parts per billion — p=<0.1
N/A N=12 Role of Eosinophils in the Proliferation of Airway Smooth Muscle (ASM) Cells
Asthma
Primary: Fold Increase in ASM Proliferation Following Incubation With Eosinophils. — 2; 2 Fold increase in ASM cell proliferation — p=<0.05
N/A N=30 Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Nasal Polyps · Aspirin-exacerbated Respiratory Disease
Primary: Number of Participants With Nasal Polyp Plasma Cell Transcriptome — 10; 10; 10 Participants
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Phase 4 N=95 Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Asthma, Aspirin-Induced · Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline at Week 16 in Sinonasal Outcome Test -22 (SNOT-22) Score — -14.09; -4.37 points
Phase 4 N=23 Steroid Treatment for Hypereosinophilic Syndrome
Eosinophilia · Hypereosinophilic Syndrome · Leukocyte Disorder
Primary: Mean Percent Change in Eosinophil Count After Glucocorticoid Challenge — -69.6; -13.6 percentage of eosinophil count
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Phase 3 N=136 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Churg-Strauss Syndrome
Primary: Number of Participants in Each Category of Accrued Duration of Remission — 55; 32; 8; 8 Participants — p=<0.001
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 3 N=108 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Hypereosinophilic Syndrome
Primary: Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During the 32-Week Study Treatment Period — 56; 28 Percentage of participants…
N/A N=38 Eosinophilic Airway Inflammation and Mepolizumab
Asthma
Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…
Phase 4 N=313 Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Asthma
Primary: Asthma Control — 312; 72; 0; 229 Participants
Phase 4 N=30 Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways Diseases
Chronic Cough · Eosinophilic Bronchitis · Asthma
Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99
Phase 2 N=46 Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
Asthma, Aspirin-Induced · Aspirin Exacerbated Asthma
Primary: Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo — 79; 139 mg
N/A N=15 Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers
Tobacco Abuse Smoke
Primary: Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo — 40.9; 0.0 % change
Phase 4 N=105 The Effects of Montelukast on Smokers With Asthma
Asthmatic Smokers · Non-asthmatic Smokers
Primary: Sputum Neutrophil Percentages — 86.00; 72.53; 89.33; 79.84 percentage of neutrophils
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
Phase 2 N=60 Preschool Wheeze: Inflammation/Infection Guided Management
Asthma
Primary: Number of Unscheduled Healthcare Visits (UHCV) — 0.5; 0.5 number of visits — p=0.05
N/A N=389 Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)
Condition of Patient 3 Years After FESS-operation
Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants
Phase 3 N=26 Benralizumab for Eosinophilic Gastritis (BEGS)
Eosinophilic Gastritis or Gastroenteritis
Primary: Percent of Patients in Histological Remission (<30 Eos/Hpf) — 77; 8 percentage of participants — p=0.0001
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078